Cytox Limited provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia. Cytox’s mission is to transform how new treatments are developed, people are screened, and how patients are managed within the Alzheimer’s disease care pathway.

Alzheimer’s disease today affects over 46 million people globally, projected to reach 75 million in 2030 and over 131 million people by 2050 with an economic impact estimated to exceed $1tn per year in the next decade [World Alzheimer’s Report 2015].

In the US, Cytox has partnered with Sampled which has developed the Sampled Alzheimer’s Risk Test – powered by genoSCORE (www.alzheimers-risk-test.com).

The tests only require a blood or saliva sample. An easy-to-use saliva collection device enables elderly and vulnerable patients to provide a sample from home if they are not wishing or easily able to attend a healthcare setting. The Alzheimer’s Risk Test is available for qualified healthcare profession to order for their patient through the website.

The Alzheimer’s Risk Test assesses an individual’s genetic risk of cognitive decline due to Alzheimer’s disease. The test's primary application is for physicians assessing new patients, with cognitive concerns, to assess their future risk of cognitive decline due to Alzheimer’s disease. It can also provide greater insight into the risk of cognitive decline in existing patients.